The preference for semaglutide (43.8%) and tirzepatide (26.6%) in this study mirrors the trends in [27], which found semaglutide use in 45% of participants and tirzepatide in 28%
See the full semaglutide dosage chart for the complete schedule
Phase 3 results pending Key Takeaways# Triple agonism leads -- Retatrutide's 28.7% weight loss at 68 weeks confirms that targeting three receptors (GLP-1 + GIP + glucagon) produces the most weight loss
Depression and anxiety are the most common mental health conditions in the United States, with an estimated 40 million adults suffering from an anxiety disorder, and an estimated 9.5% of adults suffering from a depressive illness each year
Semaglutide, on the other hand, has become a widely used medication for managing chronic conditions like diabetes and obesity
Coordinate multidisciplinary care among endocrinologists, obstetricians, and reproductive specialists to optimize timing of therapy and transition